[
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.",
    "summary": "For more than a year, Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema.  On Friday, Novo released the results of a large Phase 3 trial of the drug.  Patients lost only 22.7% of their body weight, on average, after about a year and a half.",
    "url": "https://finnhub.io/api/news?id=9c26b935da435aa9465533f649c0918091a9eff0390bc1357fdd44055de83e36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734704400,
      "headline": "Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.",
      "id": 132073775,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "For more than a year, Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema.  On Friday, Novo released the results of a large Phase 3 trial of the drug.  Patients lost only 22.7% of their body weight, on average, after about a year and a half.",
      "url": "https://finnhub.io/api/news?id=9c26b935da435aa9465533f649c0918091a9eff0390bc1357fdd44055de83e36"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?",
    "summary": "Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.",
    "url": "https://finnhub.io/api/news?id=4cf84c3f876a5d6fa2670d1527b8a7fc38a198321a996917461fd441063f0142",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734735495,
      "headline": "Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?",
      "id": 132082189,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.",
      "url": "https://finnhub.io/api/news?id=4cf84c3f876a5d6fa2670d1527b8a7fc38a198321a996917461fd441063f0142"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their sleep disorder. It should be used with a reduced-calorie diet and increased physical activity.",
    "url": "https://finnhub.io/api/news?id=334bb356544192ce1f3a80d09cb1e85a292c01609d4dade2b507c41f779f5cbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734730320,
      "headline": "FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity",
      "id": 132087591,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their sleep disorder. It should be used with a reduced-calorie diet and increased physical activity.",
      "url": "https://finnhub.io/api/news?id=334bb356544192ce1f3a80d09cb1e85a292c01609d4dade2b507c41f779f5cbd"
    }
  },
  {
    "ts": null,
    "headline": "Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.",
    "summary": "Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.",
    "url": "https://finnhub.io/api/news?id=dc041da50e6e44284cc65bce2bc914dfd8fabf08d2b05a05c3ef84355fb1c036",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734719769,
      "headline": "Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.",
      "id": 132079421,
      "image": "https://media.zenfs.com/en/ibd.com/46c18cf5ac864a5f2306cbef485a793d",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.",
      "url": "https://finnhub.io/api/news?id=dc041da50e6e44284cc65bce2bc914dfd8fabf08d2b05a05c3ef84355fb1c036"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients",
    "summary": "Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients",
    "url": "https://finnhub.io/api/news?id=dfbde3d0b0979120b41aaa184c633336ac9b6a6ae7a9a1497604c8c7884ee2cc",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734725100,
      "headline": "Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients",
      "id": 132145540,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients",
      "url": "https://finnhub.io/api/news?id=dfbde3d0b0979120b41aaa184c633336ac9b6a6ae7a9a1497604c8c7884ee2cc"
    }
  },
  {
    "ts": null,
    "headline": "Novo’s Obesity Shot Shortfall Shows Danger of Promising Too Much",
    "summary": "(Bloomberg) -- Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs.Most Read from BloombergThe Architects Who Built MiamiNew York City’s Historic Preservation Movement Is Having a Midlife CrisisReviving a Little-Known Modernist Landmark in BuffaloNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNYPD Car Chases Are Becoming More Frequent — and More DangerousThe",
    "url": "https://finnhub.io/api/news?id=25d2837f42b3fad6ef9074c953b1eb07b51587cae56ca3c6545b342e1a16c97e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734718187,
      "headline": "Novo’s Obesity Shot Shortfall Shows Danger of Promising Too Much",
      "id": 132085197,
      "image": "https://s.yimg.com/ny/api/res/1.2/F9sfHLtHBOL1m2e5iyfLJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03Mjg-/https://media.zenfs.com/en/bloomberg_technology_68/b990977e787c6af4b364125015202ba9",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs.Most Read from BloombergThe Architects Who Built MiamiNew York City’s Historic Preservation Movement Is Having a Midlife CrisisReviving a Little-Known Modernist Landmark in BuffaloNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNYPD Car Chases Are Becoming More Frequent — and More DangerousThe",
      "url": "https://finnhub.io/api/news?id=25d2837f42b3fad6ef9074c953b1eb07b51587cae56ca3c6545b342e1a16c97e"
    }
  },
  {
    "ts": null,
    "headline": "There’s a New Obesity King",
    "summary": "Eli Lilly is now comfortably ahead of Novo Nordisk in the race to dominate the market for obesity treatments.",
    "url": "https://finnhub.io/api/news?id=7e35788ad9716878a54c89edb79cc7fe49fc5c04357d919a7dfd741bf9d1447f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734718020,
      "headline": "There’s a New Obesity King",
      "id": 132087597,
      "image": "https://s.yimg.com/ny/api/res/1.2/uE_YBF4SQDQqMwG9xuSxew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/3666e1db0c35222a46ac624ec8b0592b",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is now comfortably ahead of Novo Nordisk in the race to dominate the market for obesity treatments.",
      "url": "https://finnhub.io/api/news?id=7e35788ad9716878a54c89edb79cc7fe49fc5c04357d919a7dfd741bf9d1447f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients -- Update",
    "summary": "By Stephen Nakrosis Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The company said Zepbound, or...",
    "url": "https://finnhub.io/api/news?id=41e34df5e587334985131faa150f0f7746e5edeb7794a582b15b50d95cf386fc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734716713,
      "headline": "Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients -- Update",
      "id": 132080755,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Stephen Nakrosis Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The company said Zepbound, or...",
      "url": "https://finnhub.io/api/news?id=41e34df5e587334985131faa150f0f7746e5edeb7794a582b15b50d95cf386fc"
    }
  },
  {
    "ts": null,
    "headline": "Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up",
    "summary": "Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.",
    "url": "https://finnhub.io/api/news?id=435bbf19093ee0cfd04f675b64d84211a5c50e1b66c0c0e531ed706126c9ffe6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734715225,
      "headline": "Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up",
      "id": 132083866,
      "image": "https://g.foolcdn.com/editorial/images/801777/package-of-weight-loss-drug-next-to-a-barbell.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.",
      "url": "https://finnhub.io/api/news?id=435bbf19093ee0cfd04f675b64d84211a5c50e1b66c0c0e531ed706126c9ffe6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Says FDA Approves Zepbound for Obstructive Sleep Apnea in Adults With Obesity",
    "summary": "By Stephen Nakrosis Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The company said Zepbound, or...",
    "url": "https://finnhub.io/api/news?id=e9d2e952bd24b09521007202ce4d3b9f146aff85d684ca9fd8a196ec1ad56206",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734714428,
      "headline": "Eli Lilly Says FDA Approves Zepbound for Obstructive Sleep Apnea in Adults With Obesity",
      "id": 132080324,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Stephen Nakrosis Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The company said Zepbound, or...",
      "url": "https://finnhub.io/api/news?id=e9d2e952bd24b09521007202ce4d3b9f146aff85d684ca9fd8a196ec1ad56206"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea",
    "summary": "The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with...",
    "url": "https://finnhub.io/api/news?id=6c548a36914a6e7c70b2bf159aa107ff3b030beb2eb3fd798f8c0dfa427e2864",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734712899,
      "headline": "Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea",
      "id": 132079957,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with...",
      "url": "https://finnhub.io/api/news?id=6c548a36914a6e7c70b2bf159aa107ff3b030beb2eb3fd798f8c0dfa427e2864"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic maker’s shares plunge after failed weight-loss trial",
    "summary": "Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set of underwhelming results in a trial for its next-generation obesity drug.",
    "url": "https://finnhub.io/api/news?id=2d9f3d6d9639b46cea80ec5b2196714ac340113c543c49992703d0a99290a5a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734712708,
      "headline": "Ozempic maker’s shares plunge after failed weight-loss trial",
      "id": 132085208,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set of underwhelming results in a trial for its next-generation obesity drug.",
      "url": "https://finnhub.io/api/news?id=2d9f3d6d9639b46cea80ec5b2196714ac340113c543c49992703d0a99290a5a0"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's New Weight-Loss Drug Lags Behind Eli Lilly's Zepbound",
    "summary": "Novo Nordisk's new weight-loss drug, CagriSema, missed the company's target in Phase 3 trials, causing a 20.37% drop in shares.",
    "url": "https://finnhub.io/api/news?id=1819d14f748276106bc96adbc782d793ebe22e07d8e45528882d5c07b1e84112",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734710966,
      "headline": "Novo Nordisk's New Weight-Loss Drug Lags Behind Eli Lilly's Zepbound",
      "id": 132085210,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/aa6e73c90c570f4f612a8395ddab3318",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's new weight-loss drug, CagriSema, missed the company's target in Phase 3 trials, causing a 20.37% drop in shares.",
      "url": "https://finnhub.io/api/news?id=1819d14f748276106bc96adbc782d793ebe22e07d8e45528882d5c07b1e84112"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results",
    "summary": "Novo Nordisk stock sinks on news of its newest GLP-1 candidate.",
    "url": "https://finnhub.io/api/news?id=667ae2b99b9d6a489fea6c381bc5c75ac118800113d759ed49d7400a21581bd7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734710618,
      "headline": "Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results",
      "id": 132078658,
      "image": "https://s.yimg.com/ny/api/res/1.2/n2s.AVsYyb1YMkjOd8DlBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03ODc-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/08d95520-bedf-11ef-afe5-bfb97e1ec4f1",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock sinks on news of its newest GLP-1 candidate.",
      "url": "https://finnhub.io/api/news?id=667ae2b99b9d6a489fea6c381bc5c75ac118800113d759ed49d7400a21581bd7"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Plunges 20% After Weight-Loss Drug Trial Misses Target",
    "summary": "Investors flee as Novo's CagriSema trial falls short, erasing $125 billion in market value.",
    "url": "https://finnhub.io/api/news?id=5f79fc17c068c7882054e2f30bfe9d0e9f651eea35bfb2cbf0d6e414d25bf338",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734708224,
      "headline": "Novo Nordisk Plunges 20% After Weight-Loss Drug Trial Misses Target",
      "id": 132085218,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/aa6e73c90c570f4f612a8395ddab3318",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors flee as Novo's CagriSema trial falls short, erasing $125 billion in market value.",
      "url": "https://finnhub.io/api/news?id=5f79fc17c068c7882054e2f30bfe9d0e9f651eea35bfb2cbf0d6e414d25bf338"
    }
  },
  {
    "ts": null,
    "headline": "Why Novo Nordisk (NVO) Is Plummeting Today",
    "summary": "Novo Nordisk (NVO) stock is tumbling 21% today after individuals who received the company’s experimental weight-loss drug shed many fewer pounds than expected. Specifically, the weight of patients who received Novo’s anti-obesity drug, CagriSema, declined by an average of 20.4% in 68 weeks, versus the 25% average weight loss that Novo had expected the treatment […]",
    "url": "https://finnhub.io/api/news?id=892e44aba6879c3ad3f715f06272485c097a3ecde7b50ad516c77b252f0bc322",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734707652,
      "headline": "Why Novo Nordisk (NVO) Is Plummeting Today",
      "id": 132085220,
      "image": "https://s.yimg.com/ny/api/res/1.2/jsQ2IS9SAFjb7st2wjya1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/6a3eb9e1b9760b4bed78b16d1253664c",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO) stock is tumbling 21% today after individuals who received the company’s experimental weight-loss drug shed many fewer pounds than expected. Specifically, the weight of patients who received Novo’s anti-obesity drug, CagriSema, declined by an average of 20.4% in 68 weeks, versus the 25% average weight loss that Novo had expected the treatment […]",
      "url": "https://finnhub.io/api/news?id=892e44aba6879c3ad3f715f06272485c097a3ecde7b50ad516c77b252f0bc322"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Equity Strategist on Novo Setback",
    "summary": "-- As Novo Nordisk experimental drug falls short of target, Mizuho Securities Healthcare Equity Strategist Jared Holz says Eli Lilly will remain the market leader. Holz also speaks with Scarlet Fu...",
    "url": "https://finnhub.io/api/news?id=f17866e62f125d04a4a7d450afabcfa6a4b7a8ae129abc6b225edc871b943bc9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734707408,
      "headline": "Healthcare Equity Strategist on Novo Setback",
      "id": 132078512,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "-- As Novo Nordisk experimental drug falls short of target, Mizuho Securities Healthcare Equity Strategist Jared Holz says Eli Lilly will remain the market leader. Holz also speaks with Scarlet Fu...",
      "url": "https://finnhub.io/api/news?id=f17866e62f125d04a4a7d450afabcfa6a4b7a8ae129abc6b225edc871b943bc9"
    }
  },
  {
    "ts": null,
    "headline": "LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List",
    "summary": "Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.",
    "url": "https://finnhub.io/api/news?id=5e992d2a90b4d4210114a3cb85532c1f0c776e3bbe098dd3a76fd5a7427ff8b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734707100,
      "headline": "LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List",
      "id": 132085221,
      "image": "https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.",
      "url": "https://finnhub.io/api/news?id=5e992d2a90b4d4210114a3cb85532c1f0c776e3bbe098dd3a76fd5a7427ff8b4"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk stock plunges on obesity shot trial results",
    "summary": "Novo Nordisk (NVO) is falling by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted in its clinical trial. Yahoo Finance senior health reporter Anjalee Khemlani expands upon this story and compares Novo Nordisk's stock performance with that of GLP-1 drug competitor Eli Lilly (LLY). To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=12399af447c112c8e26d8f4e296756773af00cc744e6f70e87dc39d4dbc94164",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734705555,
      "headline": "Novo Nordisk stock plunges on obesity shot trial results",
      "id": 132073774,
      "image": "https://s.yimg.com/ny/api/res/1.2/LRrd6uFak3zCYBrCYH8p5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/172fae80-bedf-11ef-a33f-529734f6795b",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO) is falling by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted in its clinical trial. Yahoo Finance senior health reporter Anjalee Khemlani expands upon this story and compares Novo Nordisk's stock performance with that of GLP-1 drug competitor Eli Lilly (LLY). To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=12399af447c112c8e26d8f4e296756773af00cc744e6f70e87dc39d4dbc94164"
    }
  },
  {
    "ts": null,
    "headline": "November PCE, govt. shutdown looms, Novo Nordisk: 3 Things",
    "summary": "US stock futures (ES=F, NQ=F, YM=F) are slipping Friday morning after the Personal Consumption Expenditures (PCE) price index rose by 2.8% in November, just 0.1% below economists' estimates A government shutdown looms after House Speaker Mike Johnson's (R-La.) bipartisan spending bill was rebuffed by President-elect Donald Trump and Elon Musk, who Trump tapped to co-lead the proposed Department of Government Efficiency (DOGE). Novo Nordisk (NVO) shares dive by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema helped patients lose less weight than anticipated in its clinical trial. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=f2aa71970d0e62fa4c01c9a837568286d85626b2a4e2f1afa0e8540c7d8d1ac9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734704102,
      "headline": "November PCE, govt. shutdown looms, Novo Nordisk: 3 Things",
      "id": 132073777,
      "image": "https://s.yimg.com/ny/api/res/1.2/Icg53TlVxwXsM9.f9fEXsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/cae9d7a0-bedc-11ef-adef-5a036a10f20e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US stock futures (ES=F, NQ=F, YM=F) are slipping Friday morning after the Personal Consumption Expenditures (PCE) price index rose by 2.8% in November, just 0.1% below economists' estimates A government shutdown looms after House Speaker Mike Johnson's (R-La.) bipartisan spending bill was rebuffed by President-elect Donald Trump and Elon Musk, who Trump tapped to co-lead the proposed Department of Government Efficiency (DOGE). Novo Nordisk (NVO) shares dive by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema helped patients lose less weight than anticipated in its clinical trial. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=f2aa71970d0e62fa4c01c9a837568286d85626b2a4e2f1afa0e8540c7d8d1ac9"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Falls Most on Record After New Weight Drug Disappoints",
    "summary": "(Bloomberg) -- Novo Nordisk A/S’s shares fell by the most on record after a failed attempt to leapfrog rival Eli Lilly & Co. in the red-hot market for obesity drugs. Most Read from BloombergNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets as Saharan Dust Descends on SenegalRescuing a Little-Known Modernist Landmark in BuffaloNovo’s experimental obesity shot CagriSema helped patient",
    "url": "https://finnhub.io/api/news?id=848ccb7fd66ebcb79e2bf32c6ffe009fa63c1058571d7181e9a7370ed6a808b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734701603,
      "headline": "Novo Nordisk Falls Most on Record After New Weight Drug Disappoints",
      "id": 132073778,
      "image": "https://s.yimg.com/ny/api/res/1.2/k3aSY1TIg_XOeL1w5slylQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_technology_68/2eb27f916d9ad1a488bb98b4858b1296",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Novo Nordisk A/S’s shares fell by the most on record after a failed attempt to leapfrog rival Eli Lilly & Co. in the red-hot market for obesity drugs. Most Read from BloombergNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets as Saharan Dust Descends on SenegalRescuing a Little-Known Modernist Landmark in BuffaloNovo’s experimental obesity shot CagriSema helped patient",
      "url": "https://finnhub.io/api/news?id=848ccb7fd66ebcb79e2bf32c6ffe009fa63c1058571d7181e9a7370ed6a808b8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now",
    "summary": "The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See why I remain bullish on LLY stock.",
    "url": "https://finnhub.io/api/news?id=70e31d962ea4e1f0ba244334cafe782b8beb069778a38226fd180dacf153314c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734698733,
      "headline": "Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now",
      "id": 132076164,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See why I remain bullish on LLY stock.",
      "url": "https://finnhub.io/api/news?id=70e31d962ea4e1f0ba244334cafe782b8beb069778a38226fd180dacf153314c"
    }
  },
  {
    "ts": null,
    "headline": "FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation",
    "summary": "Manufacturers of compounded versions of Mounjaro now have a deadline to halt production.",
    "url": "https://finnhub.io/api/news?id=46c1178119b93e64626f0aab540b05437ae744601452a749fc8872eb08f311ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734698383,
      "headline": "FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation",
      "id": 132073049,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/GettyImages-2092473215.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Manufacturers of compounded versions of Mounjaro now have a deadline to halt production.",
      "url": "https://finnhub.io/api/news?id=46c1178119b93e64626f0aab540b05437ae744601452a749fc8872eb08f311ac"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar.",
    "summary": "Novo Nordisk  stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and Wegovy, posted disappointing clinical trial data for its experimental obesity drug CagriSema.  Novo’s American depositary receipts, or ADRs, fell as much as 28% after the news and is now down 18% to $83.87 in premarket trading.  Patients treated with Novo’s next-generation weight-loss drug CagriSema, lost an average 22.7% after 68 weeks, falling short of the 25% weight-loss target the drugmaker was expecting.",
    "url": "https://finnhub.io/api/news?id=a03cce72f1769b6a2f99e52625f3a6ccaf1333e54c1c4a687a3c90b2c7ec7f89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734696480,
      "headline": "Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar.",
      "id": 132072260,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk  stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and Wegovy, posted disappointing clinical trial data for its experimental obesity drug CagriSema.  Novo’s American depositary receipts, or ADRs, fell as much as 28% after the news and is now down 18% to $83.87 in premarket trading.  Patients treated with Novo’s next-generation weight-loss drug CagriSema, lost an average 22.7% after 68 weeks, falling short of the 25% weight-loss target the drugmaker was expecting.",
      "url": "https://finnhub.io/api/news?id=a03cce72f1769b6a2f99e52625f3a6ccaf1333e54c1c4a687a3c90b2c7ec7f89"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.",
    "summary": "Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped",
    "url": "https://finnhub.io/api/news?id=936f47d99c8a4549bb27b69c5bd0f2d3c76323b59add70e122ba8e9ecbe1c59f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734696189,
      "headline": "Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.",
      "id": 132071759,
      "image": "https://media.zenfs.com/en/ibd.com/46c18cf5ac864a5f2306cbef485a793d",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped",
      "url": "https://finnhub.io/api/news?id=936f47d99c8a4549bb27b69c5bd0f2d3c76323b59add70e122ba8e9ecbe1c59f"
    }
  },
  {
    "ts": null,
    "headline": "Stock market today: Wall Street leaps and halves its losses from what had been a dismal week",
    "summary": "NEW YORK — U.S. stocks are rallying Friday to more than halve their losses in what had been one of their worst weeks of the year. The S&P 500 jumped 1.8% and was on track for its best day in six...",
    "url": "https://finnhub.io/api/news?id=a8f197595e22efe4969f717f1e83cf5f9d6fe31e109d4b0f94ae84eeb6c4bbb7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734695925,
      "headline": "Stock market today: Wall Street leaps and halves its losses from what had been a dismal week",
      "id": 132075616,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "NEW YORK — U.S. stocks are rallying Friday to more than halve their losses in what had been one of their worst weeks of the year. The S&P 500 jumped 1.8% and was on track for its best day in six...",
      "url": "https://finnhub.io/api/news?id=a8f197595e22efe4969f717f1e83cf5f9d6fe31e109d4b0f94ae84eeb6c4bbb7"
    }
  },
  {
    "ts": null,
    "headline": "Stock market today: Wall Street rallies to trim its losses from a rough week",
    "summary": "NEW YORK — U.S. stocks are rallying Friday to trim their losses in what had been one of the market's roughest weeks of the year.The S&P 500 climbed 1.2% and was on track for its best day in six...",
    "url": "https://finnhub.io/api/news?id=5332e8e76770558c6637522c001627867124bd9cdfdde07941808f416bf145f1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734694385,
      "headline": "Stock market today: Wall Street rallies to trim its losses from a rough week",
      "id": 132075161,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "NEW YORK — U.S. stocks are rallying Friday to trim their losses in what had been one of the market's roughest weeks of the year.The S&P 500 climbed 1.2% and was on track for its best day in six...",
      "url": "https://finnhub.io/api/news?id=5332e8e76770558c6637522c001627867124bd9cdfdde07941808f416bf145f1"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints",
    "summary": "Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value.  The lower-than-expected weight loss from the drug candidate deals a blow to the Danish company's ambitions for a successor to its popular Wegovy that is more powerful than Eli Lilly's rival Zepbound, also known as Mounjaro.  Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.",
    "url": "https://finnhub.io/api/news?id=5ea0ffc6982f19e219a28d88da559c5dbe2dc0834a27808a347b4fb5eff33da3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734691886,
      "headline": "Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints",
      "id": 132071761,
      "image": "https://media.zenfs.com/en/reuters.com/a5e16515936647c769392db959fe10b1",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value.  The lower-than-expected weight loss from the drug candidate deals a blow to the Danish company's ambitions for a successor to its popular Wegovy that is more powerful than Eli Lilly's rival Zepbound, also known as Mounjaro.  Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.",
      "url": "https://finnhub.io/api/news?id=5ea0ffc6982f19e219a28d88da559c5dbe2dc0834a27808a347b4fb5eff33da3"
    }
  },
  {
    "ts": null,
    "headline": "Stock market today: Wall Street climbs to trim its losses from a rough week",
    "summary": "NEW YORK — U.S. stocks are rising Friday to trim their losses in what's set to be one of their worst weeks of the year. The S&P 500 climbed 0.7% in morning trading after erasing an initial drop....",
    "url": "https://finnhub.io/api/news?id=6117bc17d0d7b4d01aa4e8acdf91c8037aefdad0d2a27a78d7d1d0dd39570325",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734691866,
      "headline": "Stock market today: Wall Street climbs to trim its losses from a rough week",
      "id": 132074591,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "NEW YORK — U.S. stocks are rising Friday to trim their losses in what's set to be one of their worst weeks of the year. The S&P 500 climbed 0.7% in morning trading after erasing an initial drop....",
      "url": "https://finnhub.io/api/news?id=6117bc17d0d7b4d01aa4e8acdf91c8037aefdad0d2a27a78d7d1d0dd39570325"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial",
    "summary": "Novo Nordisk shares dropped after REDEFINE-1 trial disappointment. Find out why NVO stock could still offer long-term growth despite the underperformance.",
    "url": "https://finnhub.io/api/news?id=a5ea9f683639f0ae9d690e47017ace731118bff07fdf8a4866635aba785a5c9e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734689316,
      "headline": "Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial",
      "id": 132074088,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/500056694/image_500056694.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk shares dropped after REDEFINE-1 trial disappointment. Find out why NVO stock could still offer long-term growth despite the underperformance.",
      "url": "https://finnhub.io/api/news?id=a5ea9f683639f0ae9d690e47017ace731118bff07fdf8a4866635aba785a5c9e"
    }
  },
  {
    "ts": null,
    "headline": "FedEx stock boosts S&P 500 as Wall Street cheers freight spinoff plan",
    "summary": "FedEx stock boosts S&P 500 as Wall Street cheers freight spinoff plan",
    "url": "https://finnhub.io/api/news?id=0a8f548c4df35b46b0a1e473335668ff9e1ff852c43530181cc082269eaf4312",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734688035,
      "headline": "FedEx stock boosts S&P 500 as Wall Street cheers freight spinoff plan",
      "id": 132145563,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "FedEx stock boosts S&P 500 as Wall Street cheers freight spinoff plan",
      "url": "https://finnhub.io/api/news?id=0a8f548c4df35b46b0a1e473335668ff9e1ff852c43530181cc082269eaf4312"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints",
    "summary": "Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints",
    "url": "https://finnhub.io/api/news?id=d2472262222aaa23fe7656dd8729da89902d777992d96942b824d59bf35bb372",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734686760,
      "headline": "Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints",
      "id": 132145564,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints",
      "url": "https://finnhub.io/api/news?id=d2472262222aaa23fe7656dd8729da89902d777992d96942b824d59bf35bb372"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock: A Rare Buying Opportunity",
    "summary": "Financial writer sees Novo Nordisk's stock drop as a buying opportunity after disappointing trial results, citing strong revenue growth and product...",
    "url": "https://finnhub.io/api/news?id=b6c6170546309088bcba07b167de109442f05a9c7ff2ab4b7996992ce69684b8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734686117,
      "headline": "Novo Nordisk Stock: A Rare Buying Opportunity",
      "id": 132073307,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/104018545/image_104018545.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Financial writer sees Novo Nordisk's stock drop as a buying opportunity after disappointing trial results, citing strong revenue growth and product...",
      "url": "https://finnhub.io/api/news?id=b6c6170546309088bcba07b167de109442f05a9c7ff2ab4b7996992ce69684b8"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Futures Drop in Premarket Trading; Nike, Paramount Global Lag",
    "summary": "S&P 500 Futures Drop in Premarket Trading; Nike, Paramount Global Lag",
    "url": "https://finnhub.io/api/news?id=66103b3ae4bc7496d2ca277cc9ca617ca6e139cae94f03a9a6a2c86d9e5dddc1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734679800,
      "headline": "S&P 500 Futures Drop in Premarket Trading; Nike, Paramount Global Lag",
      "id": 132145565,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "S&P 500 Futures Drop in Premarket Trading; Nike, Paramount Global Lag",
      "url": "https://finnhub.io/api/news?id=66103b3ae4bc7496d2ca277cc9ca617ca6e139cae94f03a9a6a2c86d9e5dddc1"
    }
  },
  {
    "ts": null,
    "headline": "Novo’s next-gen obesity drug misses expectations in closely watched trial",
    "summary": "Novo shares lost nearly a quarter of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.",
    "url": "https://finnhub.io/api/news?id=4ac89aa3fabef2ab0bf699ae2155b92a3e7ae508b7b62028f2787390cb32a055",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734678360,
      "headline": "Novo’s next-gen obesity drug misses expectations in closely watched trial",
      "id": 132072266,
      "image": "https://imgproxy.divecdn.com/TMc0sR5V6SErvIMkrDNdSFpN1yaL0pSJ9qyeRHYrRBQ/g:nowe:7:772/c:1992:1125/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9vcmlnaW5hbF8xLmpmaWY=.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo shares lost nearly a quarter of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.",
      "url": "https://finnhub.io/api/news?id=4ac89aa3fabef2ab0bf699ae2155b92a3e7ae508b7b62028f2787390cb32a055"
    }
  },
  {
    "ts": null,
    "headline": "Stock Markets Face a Government Shutdown After Fed Selloff. What History Says Happens Next and 5 Other Things to Know Today.",
    "summary": "Stock Markets Face a Government Shutdown After Fed Selloff. What History Says Happens Next and 5 Other Things to Know Today.",
    "url": "https://finnhub.io/api/news?id=fc8c587eed0b03058eeaeddaa4d41c00025ae6746a8f43d95c08c070510377f1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734676980,
      "headline": "Stock Markets Face a Government Shutdown After Fed Selloff. What History Says Happens Next and 5 Other Things to Know Today.",
      "id": 132145566,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Stock Markets Face a Government Shutdown After Fed Selloff. What History Says Happens Next and 5 Other Things to Know Today.",
      "url": "https://finnhub.io/api/news?id=fc8c587eed0b03058eeaeddaa4d41c00025ae6746a8f43d95c08c070510377f1"
    }
  },
  {
    "ts": null,
    "headline": "Premarket movers: FedEx, Eli Lilly, Nike",
    "summary": "Premarket movers: FedEx, Eli Lilly, Nike",
    "url": "https://finnhub.io/api/news?id=9b97ea0dc60d688d8de5bae3f148afebe952e0be433d8363570972e5011e8b92",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734675603,
      "headline": "Premarket movers: FedEx, Eli Lilly, Nike",
      "id": 132145567,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Premarket movers: FedEx, Eli Lilly, Nike",
      "url": "https://finnhub.io/api/news?id=9b97ea0dc60d688d8de5bae3f148afebe952e0be433d8363570972e5011e8b92"
    }
  },
  {
    "ts": null,
    "headline": "In weight loss battle, Novo and Lilly face growing offensive from licensed copies",
    "summary": "As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a threat to the pharma giants' prices and market share.  Since Novo's blockbuster Ozempic diabetes treatment was approved in the United States in 2017, regulators have greenlighted 22 medicines containing its main ingredient in Bangladesh, Laos, Russia and Paraguay as well as seven copies of Lilly's rival drugs in Bangladesh, according to a Reuters review.",
    "url": "https://finnhub.io/api/news?id=e2a3843da4dba8cbf54ba6a7bb3f65bea355c4b33b477cba926102bf31ef5e75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734656586,
      "headline": "In weight loss battle, Novo and Lilly face growing offensive from licensed copies",
      "id": 132065735,
      "image": "https://media.zenfs.com/en/reuters-finance.com/7fa1f149c3c52224b2cd21758cd1eb05",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a threat to the pharma giants' prices and market share.  Since Novo's blockbuster Ozempic diabetes treatment was approved in the United States in 2017, regulators have greenlighted 22 medicines containing its main ingredient in Bangladesh, Laos, Russia and Paraguay as well as seven copies of Lilly's rival drugs in Bangladesh, according to a Reuters review.",
      "url": "https://finnhub.io/api/news?id=e2a3843da4dba8cbf54ba6a7bb3f65bea355c4b33b477cba926102bf31ef5e75"
    }
  }
]